PXD005611-2

PXD005611 is an original dataset announced via ProteomeXchange.

Title	Resistance to Palbociclib requires multiple targetable mechanisms highlighting the potential of drug holidays and drug switching to improve therapeutic outcome
Description	Estrogen receptor positive (ER+) breast cancer is the most common type of breast cancer. Despite the great efficacy of endocrine therapies, resistance remains a problem. Therefore, there is an immediate need for new, effective therapies in ER+ BC. In this study, we have explored the role of a potent CDK4/6 inhibitor called palbociclib. In order to identify alterations in protein abundance between the responsive and resistant setting, we generated a panel of palbociclib-sensitive and resistant cell lines and did quantitative, shotgun proteomics using dimethyl labelling. Palbociclib sensitive cell lines (wt-MCF7 or MCF7-LTED) were cultured in phenol red-free RPMI supplemented with 10% FBS and 1nM estradiol or 10% dextran-coated charcoal (DCC) respectively. Thereafter, palbociclib resistant cell lines were generated using 1μΜ palbociclib concentration. Samples were harvested at baseline and at the point of resistance.
HostingRepository	PRIDE
AnnounceDate	2020-03-25
AnnouncementXML	Submission_2020-06-12_03:59:03.xml
DigitalObjectIdentifier
ReviewLevel	Peer-reviewed dataset
DatasetOrigin	Original dataset
RepositorySupport	Unsupported dataset by repository
PrimarySubmitter	Nikiana Simigdala
SpeciesList	scientific name: Homo sapiens (Human); NCBI TaxID: 9606;
ModificationList	monohydroxylated residue; iodoacetamide derivatized residue
Instrument	LTQ Orbitrap Velos

Revision	Datetime	Status	ChangeLog Entry
0	2016-12-21 01:41:13	ID requested
1	2020-03-24 23:19:27	announced
⏵ 2	2020-06-12 03:59:04	announced	2020-06-12: Updated publication reference for PubMed record(s): 32307447.
3	2024-10-22 05:01:26	announced	2024-10-22: Updated project metadata.

Pancholi S, Ribas R, Simigdala N, Schuster E, Nikitorowicz-Buniak J, Ressa A, Gao Q, Leal MF, Bhamra A, Thornhill A, Morisset L, Montaudon E, Sourd L, Fitzpatrick M, Altelaar M, Johnston SR, Marangoni E, Dowsett M, Martin LA, Tumour kinome re-wiring governs resistance to palbociclib in oestrogen receptor positive breast cancers, highlighting new therapeutic modalities. Oncogene, 39(25):4781-4797(2020) [pubmed]

curator keyword: Biomedical

submitter keyword: Palbociclib, resistance, proteomics, breast cancer

Lesley-Ann Martin
contact affiliation	Breast Cancer Now The Institute of Cancer Research
contact email	Lesley-Ann.Martin@icr.ac.uk
lab head
Nikiana Simigdala
contact affiliation	The Institute of Cancer Research
contact email	Nikiana.Simigdala@icr.ac.uk
dataset submitter

Dataset FTP location NOTE: Most web browsers have now discontinued native support for FTP access within the browser window. But you can usually install another FTP app (we recommend FileZilla) and configure your browser to launch the external application when you click on this FTP link. Or otherwise, launch an app that supports FTP (like FileZilla) and use this address: ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/03/PXD005611

PRIDE project URI

• PRIDE
  1. PXD005611
     1. Label: PRIDE project
     2. Name: Resistance to Palbociclib requires multiple targetable mechanisms highlighting the potential of drug holidays and drug switching to improve therapeutic outcome